Publicaciones en colaboración con investigadores/as de Hospital de Galdakao - Usansolo (10)

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

2021

  1. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

  2. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2015

  1. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?

    PLoS ONE, Vol. 10, Núm. 6

  2. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2012

  1. Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism

    Journal of Thrombosis and Haemostasis, Vol. 10, Núm. 5, pp. 751-759

2007

  1. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

    Leukemia, Vol. 21, Núm. 1, pp. 143-150